Sanela Tarabar
Pfizer (United States)(US)
Publications by Year
Research Areas
Dermatology and Skin Diseases, Cytokine Signaling Pathways and Interactions, Pain Mechanisms and Treatments, Psoriasis: Treatment and Pathogenesis, Allergic Rhinitis and Sensitization
Most-Cited Works
- → Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia(2016)196 cited
- → Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults(2019)100 cited
- → Inherited erythromelalgia due to mutations inSCN9A:natural history, clinical phenotype and somatosensory profile(2016)93 cited
- → Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study(2020)66 cited
- → Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study(2022)61 cited
- → Hearing Loss in Migrant Agricultural Workers(2005)57 cited
- → Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study(2022)52 cited
- → Evaluation of a Janus kinase 1 inhibitor, PF‐04965842, in healthy subjects: A phase 1, randomized, placebo‐controlled, dose‐escalation study(2018)45 cited
- → First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430(2016)30 cited
- → Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study(2023)29 cited